(NASDAQ:REPL) SAN FRANCISCO, Sept. 4, 2025 /PRNewswire/ -- A new securities class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and its executives. The lawsuit alleges that the company misled investors by overstating the success of its lead cancer drug, RP1, leading to a...
Related Questions
What immediate effect will the lawsuit have on REPL's stock volatility and price?
How might the alleged misstatement about RP1's trial results affect the company's pipeline credibility and future financing?
What precedent does this case set for other biotech firms and how could it influence market perception of similar clinical trial disclosures?